



28 August 2026

Sydney, Australia

Notice of Change of Interests of Substantial Securityholder ("Notice")

Nyrada Inc (ASX: NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical condition advises that, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests ("CDIs"), a Notice of Interests Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder: Mr Mark Azzi

Date of change in the interests of the Substantial Holder: 27 August 2026

Previous and present voting power of Substantial Holder (through CHESSE Depositary Nominees Pty Ltd):

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
25,568,254	10.35%	28,326,504	11.44%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
Mr Mark Azzi	Mr Mark Azzi	27,726,504	11.20%
Mr Mark Azzi	Mr Mark Azzi	600,000	0.24%

(1) Based on 247,592,830 CDIs on issue as outlined in Appendix 2A released to ASX on 24 August 2026

NYR has provided a copy of this Notice to Mr Mark Azzi who has confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) (**Act**), including the number of equity securities or CDIs disclosed in the Notice, being 28,326,504 CDIs, and that these equity securities represent all equity securities held by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.

– ENDS –



About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by James Bonnar, Managing Director, on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “plan,” “should,” “target,” “will” or “would” or the negative of such terms or other similar expressions. Preclinical results may not translate to humans. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.